Last reviewed · How we verify
NLY01
At a glance
| Generic name | NLY01 |
|---|---|
| Also known as | Placebo, normal saline |
| Sponsor | Neuraly, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease (PHASE2)
- A Study With NLY01 in Subjects With Type 2 Diabetes (PHASE2)
- A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NLY01 CI brief — competitive landscape report
- NLY01 updates RSS · CI watch RSS
- Neuraly, Inc. portfolio CI